Novel Regimen Boosts Survival for Recurrent Platinum-Resistant Ovarian Cancer
SAN JUAN, PUERTO RICO — A novel regimen for platinum-resistant ovarian cancer solidified its role as a treatment option with a significant improvement in overall survival (OS), according to a ROSELLA trial update. Adding the glucocorticoid receptor antagonist relacorilant (Lifyorli) to nab-paclitaxel improved median overall survival (OS) by 4 months versus nab-paclitaxel alone. The regimen…
